AstraZeneca’s Nexium, Prilosec Get Clean Bill Of Health From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says there is no evidence of either proton-pump inhibitor leading to cardiovascular risk.
You may also be interested in...
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.
FDA Finds Statins Not Linked To ALS; When Can A False Alarm Be Turned Off?
FDA's determination that statins do not increase the incidence of amyotrophic lateral sclerosis suggests that agency will continue to rely on data from placebo controlled trials to address concerns raised in post-marketing reports